With regard to anti-TNF-α biosimilars specifically, an Italian Delphi consensus statement published in 2023 agreed that the cost-efficacy profile of anti-TNF-α biosimilars warrants their first-line use in IBD [58]. Here, TNF is linked to inflammatory bowel disease.